Clinical trial
Rituximab and Combination Chemotherapy in Treating Patients With Newly…
NCT00392834 · AIDS Malignancy Consortium, Other · Completed
Key facts
| NCT number | NCT00392834 |
|---|---|
| Title | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma |
| Official title | Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma |
| Lead sponsor | AIDS Malignancy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH The Emmes Company, LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, pegfilgrastim, rituximab, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, liposomal cytarabine and 3 more |
| Enrollment | 34 |
| Start date | Sep 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2013 |
| First posted | Oct 26, 2006 |
| Last update posted | Jun 6, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: